Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial

被引：0

作者：

Wolisnky, J. S. ^{[1
]}

Brochet, B. ^{[2
]}

Montalban, X. ^{[3
,4
]}

Naismith, R. T. ^{[5
]}

Manfrini, M. ^{[6
]}

Garas, M. ^{[6
]}

Villoslada, P. ^{[7
]}

Model, F. ^{[6
]}

Hubeaux, S. ^{[6
]}

Kappos, L. ^{[8
]}

Hauser, S. L. ^{[9
]}

机构：

[1] UTHealth, McGovern Med Sch, Houston, TX USA

[2] Univ Bordeaux, Bordeaux, France

[3] Univ Toronto, Div Neurol, Toronto, ON, Canada

[4] Vall dHebron Univ Hosp, Barcelona, Spain

[5] Washington Univ, Sch Med, St Louis, MO USA

[6] F Hoffmann La Roche Ltd, Basel, Switzerland

[7] Genentech Inc, San Francisco, CA 94080 USA

[8] Univ Basel, Univ Hosp Basel, Basel, Switzerland

[9] Univ Calif San Francisco, San Francisco, CA 94143 USA

来源：

MULTIPLE SCLEROSIS JOURNAL | 2018年 / 24卷

基金：

新加坡国家研究基金会;

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P910

引用

页码：490 / 491

页数：2

共 50 条

[21] Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial [J].

Wolinsky, Jerry S. ;

Arnold, Douglas L. ;

Brochet, Bruno ;

Hartung, Hans-Peter ;

Montalban, Xavier ;

Naismith, Robert T. ;

Manfrini, Marianna ;

Overell, James ;

Koendgen, Harold ;

Sauter, Annette ;

Bennett, Iain ;

Hubeaux, Stanislas ;

Kappos, Ludwig ;

Hauser, Stephen L. .

LANCET NEUROLOGY, 2020, 19 (12) :998-1009

[22] Evaluation of no evidence of progression using composite disability outcome measures, in patients with primary progressive multiple sclerosis in the ORATORIO trial. [J].

Montalban, X. ;

Arnold, D. L. ;

Bar-Or, A. ;

De Seze, J. ;

Giovannoni, G. ;

Hemmer, B. ;

Rammohan, K. ;

Masterman, D. ;

Bernasconi, C. ;

Wei, W. ;

Belachew, S. ;

Chin, P. ;

Wolinsky, J. .

MULTIPLE SCLEROSIS JOURNAL, 2016, 22 :50-51

[23] Brain MRI Activity and Atrophy Measures in Patients Receiving Continuous Ocrelizumab or Switching From Interferon Beta-1a to Ocrelizumab Therapy in the Open-Label Extension Period of the Phase III Trials of Ocrelizumab in Patients With Relapsing Multiple Sclerosis [J].

Arnold, Douglas ;

Kappos, Ludwig ;

Hauser, Stephen ;

Montalban, Xavier ;

Traboulsee, Anthony ;

Wolinsky, Jerry ;

Levesque, Victoria ;

Villoslada, Pablo ;

Belachew, Shibeshih ;

Model, Fabian ;

Hubeaux, Stanislas ;

Bar-Or, Amit .

NEUROLOGY, 2018, 90

[24] Dimethyl fumarate treatment of primary progressive multiple sclerosis: results of an open-label extension study [J].

Talbot, Jacob ;

Lundell, Henrik ;

Marstrand, Lisbet ;

Madsen, Camilla Gobel ;

Hansen, Malene Bredahl ;

Siebner, Hartwig Roman ;

Sellebjerg, Finn ;

Chow, Helene Hojsgaard ;

Sondergaard, Helle Bach ;

Sorensen, Per Solberg .

MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 70

[25] EVALUATION OF NO EVIDENCE OF PROGRESSION OR ACTIVE DISEASE (NEPAD) IN PATIENTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS IN THE ORATORIO TRIAL [J].

Wolinsky, Jerry ;

Montalban, Xavier ;

Kappos, Ludwig ;

Hauser, Stephen ;

Giovannoni, Gavin ;

de Seze, Jerome ;

Bar-Or, Amit ;

Masterman, Donna ;

Bernasconi, Corrado ;

Wei, Wei ;

Garren, Hideki ;

Chin, Peter ;

Belachew, Shibeshih ;

Arnold, Doug L. .

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2017, 88 (05)

[26] Open-label Phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS [J].

Kuhelj, R. ;

Deol-Bhullar, G. ;

Garas, M. ;

Chin, P. ;

Hauser, S. ;

Montalban, X. .

EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 :200-200

[27] Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial [J].

Montalban, X. ;

Wolinsky, J. ;

Kappos, L. ;

Hauser, S. L. ;

Giovannoni, G. ;

de Seze, J. ;

Bar-or, A. ;

Masterman, D. ;

Bernasconi, C. ;

Wei, W. ;

Garren, H. ;

Chin, P. ;

Belachew, S. ;

Arnold, D. L. .

EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 :576-576

[28] Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial [J].

Montalban, Xavier ;

Wolinsky, Jerry ;

Kappos, Ludwig ;

Hauser, Stephen L. ;

Giovannoni, Gavin ;

de Seze, Jerome ;

Bar-Or, Amit ;

Masterman, Donna ;

Bernasconi, Corrado ;

Wei, Wei ;

Garren, Hideki ;

Chin, P. ;

Belachew, S. ;

Arnold, D. L. .

MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (02) :NP10-NP10

[29] Interim analysis of an open-label extension study of sustained release fampridine in patients with multiple sclerosis [J].

Goodman, A. D. ;

Brown, T. ;

Krupp, L. ;

Schapiro, R. ;

Marinucci, L. ;

Cohen, R. ;

Blight, A. .

MULTIPLE SCLEROSIS, 2009, 15 (09) :S13-S13

[30] Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial [J].

Wolinsky, Jerry S. ;

Montalban, Xavier ;

Hauser, Stephen L. ;

Giovannoni, Gavin ;

Vermersch, Patrick ;

Bernasconi, Corrado ;

Deol-Bhullar, Gurpreet ;

Garren, Hideki ;

Chin, Peter ;

Belachew, Shibeshih ;

Kappos, Ludwig .

ANNALS OF NEUROLOGY, 2018, 84 (04) :527-536

← 1 2 3 4 5 →